- Home
- BBNX vs IMTX Comparison
BBNX vs IMTX Comparison
Compare BBNX & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBNX
- IMTX
- Stock Information
- Founded
- BBNX 2015
- IMTX N/A
- Country
- BBNX United States
- IMTX Germany
- Employees
- BBNX N/A
- IMTX N/A
- Industry
- BBNX Medical/Dental Instruments
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BBNX Health Care
- IMTX Health Care
- Exchange
- BBNX Nasdaq
- IMTX Nasdaq
- Market Cap
- BBNX 967.6M
- IMTX 865.5M
- IPO Year
- BBNX 2025
- IMTX N/A
- Fundamental
- Price
- BBNX $22.26
- IMTX $9.40
- Analyst Decision
- BBNX Strong Buy
- IMTX Strong Buy
- Analyst Count
- BBNX 10
- IMTX 5
- Target Price
- BBNX $26.10
- IMTX $15.00
- AVG Volume (30 Days)
- BBNX 1.2M
- IMTX 797.4K
- Earning Date
- BBNX 11-06-2025
- IMTX 11-17-2025
- Dividend Yield
- BBNX N/A
- IMTX N/A
- EPS Growth
- BBNX N/A
- IMTX N/A
- EPS
- BBNX N/A
- IMTX N/A
- Revenue
- BBNX $78,022,000.00
- IMTX $152,823,253.00
- Revenue This Year
- BBNX $42.80
- IMTX N/A
- Revenue Next Year
- BBNX $34.58
- IMTX N/A
- P/E Ratio
- BBNX N/A
- IMTX N/A
- Revenue Growth
- BBNX 550.45
- IMTX 83.61
- 52 Week Low
- BBNX $8.89
- IMTX $3.30
- 52 Week High
- BBNX $26.66
- IMTX $11.40
- Technical
- Relative Strength Index (RSI)
- BBNX 56.75
- IMTX 79.20
- Support Level
- BBNX $19.07
- IMTX $6.90
- Resistance Level
- BBNX $21.08
- IMTX $9.25
- Average True Range (ATR)
- BBNX 1.44
- IMTX 0.46
- MACD
- BBNX -0.45
- IMTX 0.28
- Stochastic Oscillator
- BBNX 52.15
- IMTX 99.47
About BBNX Beta Bionics Inc. Common Stock
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet.
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.